India Drug Makers Eye 10% Of Production Costs On Counterfeit Prevention
02:00 EDT 20 Aug 2012 | Elsevier Business Intelligence
Major Indian drug makers, including Elder Pharmaceuticals, Glenmark Pharmaceuticals, Lupin, Ranbaxy Laboratories and Unichem Laboratories spend as much as 10% of their generic production costs on preventing counterfeits.
Original Article: India Drug Makers Eye 10% Of Production Costs On Counterfeit Prevention
More From BioPortfolio on "India Drug Makers Eye 10% Of Production Costs On Counterfeit Prevention"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
